
As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a conversation on the updated long-term overall survival data from its Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer. Dr Link discusses SYNC-T, their investigational in situ personalised immunotherapy, as well as metastatic castration-resistant (or mCRPC) and metastatic hormone-sensitive (or mHSPC) disease, and the possible outcomes for patients going forward. Listen to the conversation and keep up on ESMO26 updates here.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Closing the global evidence gap in oncology, with Flatiron Health

Patients not just at the table, but creating their own: In conversation with Donna Cryer

AI, start-ups, and the future of human health: AION Labs’ Mati Gill

ESMO26: Taiho Oncology on improving the lives of patients with cancer, their families, and their caregivers
Free AI-powered recaps of pharmaphorum Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.